Beacon Biosignals featured in Takeda's FDA approval of Orzeyful (oveporexton) for narcolepsy type 1, the first therapy to target the underlying loss of orexin signaling rather than manage symptoms. Beacon is Takeda's neurodiagnostic partner, supplying its at-home EEG headband and FDA-cleared analytics to shorten the long diagnostic journey for narcolepsy and define objective sleep endpoints. The approval marks a milestone for a drug program that Beacon's platform helped support, underlining the company's position bringing large-scale neurophysiology into drug development.